Journal
JOURNAL OF NATURAL PRODUCTS
Volume 85, Issue 5, Pages 1419-1427Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.jnatprod.2c00246
Keywords
-
Funding
- Natural Products Support Group (NCI at Frederick)
- National Natural Science Foundation of China [81903772]
- Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research
- National Cancer Institute, National Institutes of Health [HHSN261200800001E]
Ask authors/readers for more resources
Chemical investigation of the marine hydroid Dentitheca habereri led to the discovery of eight new zoanthoxanthin alkaloids, which are the first to be reported from a hydroid. Some of these compounds show potential in inhibiting PAX3-FOXO1 transcriptional activity, making them potential candidates for drug development.
Chemical investigation of the marine hydroid Dentitheca habereri led to the identification of eight new diacylated zoanthoxanthin alkaloids, named dentithecamides A-H (1-8), along with three previously reported analogues, zoamides B-D (9-11). The structures of compounds 1-11 were elucidated by spectroscopic and spectrometric analyses, including IR, HRESIMS, and NMR experiments, and by comparison with literature data. Compounds 1-11 are the first zoanthoxanthin alkaloids to be reported from a hydroid. Dentithecamides A (1) and B (2) along with zoamides B-D (9-11), which all share a conformationally mobile cycloheptadiene core, inhibited PAX3-FOXO1 regulated transcriptional activity and thus provided a structural framework for the potential development of more potent PAX3-FOXO1 inhibitors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available